News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

EIT RawMaterials: Call for Projects 2022 is open

Published on | 3 years ago

Programmes NMBP Climate/Environment Circular Industries

Developing raw materials into a major strength for Europe

The Call for Projects 2022 is now open!

EIT RawMaterials connects stakeholders and actors from different parts of the raw materials value chain creating a unique collaborative environment for breakthrough innovations and radically new ways to address raw materials challenges. EIT RawMaterials comprises more than 120 core and associate partners from leading businesses, universities and research institutes, and an additional 190 project partners contributing to and benefitting by being involved in specific tasks in Calls for Projects.

Partners or new project partners can participate in proposals.

Monday, 19 April 2021 at 13:00 CET: Proposal registration deadline.

More information on the website: https://eitrawmaterials.eu/call-for-projects-2022-is-open/

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1488 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.